Under construction – not a live service
Sign in
Taking people in FranceNo phase

Blood Test to Predict Cytomegalovirus Flare-Ups in Ulcerative Colitis

Tests a blood test for cytomegalovirus in adults with ulcerative colitis.

Plain-language title generated from the registry record
Registry title: QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

Key facts

Where
Lyon and Saint-Etienne, FranceSee the 2 sites

Where in France

  • HCL - Hôpital Lyon SudLyon, FranceTaking people
  • CHU Saint-EtienneSaint-Etienne, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre Hospitalier Universitaire de Saint Etienne
Trial code
NCT04030676
Record updated
29 April 2025
Original description
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.Read full original descriptionShow less

Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)

CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.

Inclusion: Patient with seropositive for CytoMegaloVirus (CMV) (IgG+); Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score > 5 and an endoscopic subscore ≥ 2; Social security affiliation; Signed informed consent.

Exclusion: Wardship patient and curatorial patient; Patient unable to understand or sign the protocol; Colectomy total or partial.

ClinicalTrials.gov NCT04030676